Philippe Pierre Goupit
Presidente presso Tollys
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Patrick Kron | M | 70 | 10 anni | |
| Chris Buyse | M | 59 | 7 anni | |
| Annick Schwebig | M | 73 | 7 anni | |
| Jacques-François Martin | M | 78 |
Tollys
 Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Fabienne Lecorvaisier | F | 61 | 11 anni | |
| Dominique Rigal | M | - |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Dino Dina | M | 77 |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Olivier Antoine M. Charmeil | M | 59 | 18 anni | |
| Chahra Khaoua Epouse Louafi | F | 53 |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 8 anni |
| Vincent Charlon | M | - |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
| Kristina Meyer | M | - | 9 anni | |
| Céline Saint Olive Baque | M | - |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Serge Weinberg | M | 73 | - | |
| Marc Cluzel | M | 69 | 19 anni | |
| Jean-René Fourtou | M | 85 | - | |
| Arthur Charles V. Wellesley | M | 78 | 12 anni | |
| Christian Chavy | M | 75 |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 1 anni |
| Matthew Ros | M | 57 | 5 anni | |
| Suet-Fern Lee | F | 66 | 9 anni | |
| Bonnie Bassler | M | 61 | 2 anni | |
| Philippe Peyre | M | 73 | - | |
| Catherine Moukheibir | F | 64 |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | 5 anni |
| Jean Zetlaoui | M | - | 19 anni | |
| Ji Zhang | M | - | - | |
| Thierry Vernier | M | - | - | |
| Daniel Schirlin | M | - | - | |
| Jorge Insuasty | M | - | - | |
| Dominique Carouge | M | - | - | |
| Robert Castaigne | M | 78 | 18 anni | |
| Claudie Haigneré | M | 67 | 12 anni | |
| Carole Piwnica | F | 66 | 12 anni | |
| Uwe Bicker | M | 79 | - | |
| Muriel Bardet | F | - | 16 anni | |
| Jürgen Dormann | M | 84 | - | |
| Mishima Gerhart | F | - | 6 anni | |
| Klaus Pohle | M | 86 | 12 anni | |
| Christopher Viehbacher | M | 64 | 6 anni | |
| Gérard van Kemmel | M | 84 | - | |
| Thierry Desmarest | M | 78 | 14 anni | |
| Bernard Davitian | M | 63 |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | 4 anni |
| Adrian Senderowicz | M | 60 | 1 anni | |
| Antoine Delcour | M | - | 6 anni | |
| Heraldo Carvalho Marchezini | M | - | 4 anni | |
| Jim Robinson | M | - | 8 anni | |
| Gary Nabel | M | 70 | 8 anni | |
| Robert DeBerardine | M | - | - | |
| Thierry Bourquin | M | - | - | |
| David Loew | M | 57 | 7 anni | |
| Léopold Bertea | M | 60 | 6 anni | |
| Riccardo Perfetti | M | 64 | 11 anni | |
| Marie-Claire Simone Daveu | F | 53 | - | |
| Amit Hasija | M | 51 | 5 anni | |
| Andrew Plump | M | 58 | - | |
| Nicolas Cartier | M | 57 | 4 anni | |
| Claire Massiot-Jouault | F | 62 | 5 anni | |
| Gérard Le Fur | M | 73 | 22 anni | |
| Tao Zhu | M | 51 | 3 anni | |
| Robert Sebbag | M | 73 | 10 anni | |
| Robin E. Harkness | M | - | - | |
| Dave Stevenson | M | - | - | |
| Essy Mozaffari | M | - | - | |
| Christian Antoni | M | 62 | - | |
| Stefan Oelrich | M | 56 | 7 anni | |
| François Beloeuvre | M | - | - | |
| Anne Beal | M | 62 | - | |
| Olivier Jacquesson | M | - | - | |
| Wayne Pisano | M | 69 | - | |
| Patrick de la Chevardière | M | 67 | 2 anni | |
| Roberto Pucci | M | 60 | 9 anni | |
| Catherine Bréchignac | M | 77 | - | |
| Alice S. Bexon | M | 54 | 3 anni | |
| Frédéric Joël Desdouits | M | 57 | 1 anni | |
| David Meeker | M | 69 | 4 anni | |
| Laurent Attal | M | 66 | 9 anni | |
| Jean-Claude Leroy | M | - | - | |
| Elias Zerhouni | M | 72 | 8 anni | |
| Thomas DesRosier | M | 69 | 2 anni | |
| Christian Mulliez | M | 63 | 15 anni | |
| Jean-Marc Bruel | M | - | 6 anni | |
| Igor Landau | M | 79 | 11 anni | |
| Jean-François Dehecq | M | 84 | 11 anni | |
| Frédéric Revah | M | 62 | 6 anni | |
| Karen Linehan | F | 65 | 25 anni | |
| Laure Thibaud | F | - | - | |
| Christophe Francois Gourlet | M | - | - | |
| Bruno Ménard | M | - | - | |
| Anne Michelle Whitaker | F | 56 | 3 anni | |
| Jez Moulding | M | - | - | |
| Paul Herbert Chew | M | 72 | 3 anni | |
| Nicolas Besse | M | 59 | 2 anni | |
| Jean-Luc Lowinski | M | 60 | - | |
| Michael Kamarck | M | 73 | - | |
| Jean-Pierre Lehner | M | - | 4 anni | |
| Franck Hamalian | M | - | - | |
| Pierre Chancel | M | 67 | - | |
| Mauro Gabella | M | 72 | 5 anni | |
| Frank Stonebanks | M | - | 5 anni | |
| George Parker | M | - | 2 anni | |
| Philippe Luscan | M | 62 | 15 anni | |
| Jean-Philippe Collin | M | 67 | 7 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Francia | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Philippe Pierre Goupit
- Contatti personali
